Influenza A H7N9 A/Anhui/1/2013, Neuraminidase Antibodies
![Anti-Influenza A H7N9 A/Anhui/1/2013, Neuraminidase [7F8] Antibody](https://www.kerafast.com/MediaStorage/Product/Images/Large/1046_2001202001263210450.jpg "Anti-Influenza A H7N9 A/Anhui/1/2013, Neuraminidase [7F8] Antibody")
These mouse monoclonal antibodies (IgG1) were raised against the NA of influenza A H7N9 virus A/Anhui/1/2013.
Highlights:
- React with the NA of influenza A H7N9 viruses
- Cross react with the NA of an H11N9 virus (A/tern/Australia/G70C/75)
- Bind to epitopes containing residues 253 (2F6), 334 (7F8), and 370 and 434 (10F4)
- Suitable for ELISA, immunofluorescence assay and NA inhibition assay
- Can be used in NA potency assessment of pre-pandemic H7N9 influenza vaccines
Influenza A H7N9 virus normally infects avian populations but a novel H7N9 reassortant virus emerged in 2013 has caused infections in humans, with ~40% mortality in the confirmed clinical cases. Symptoms include fever, cough, and shortness of breath, which may progress to severe pneumonia. Neuraminidase (NA) is one of the major surface glycoproteins on influenza virus and NA-specific immunity has been shown to provide protection against virus infection. NA is also the major target of FDA-approved antivirals that are used in treating influenza.
From the laboratory of Hongquan Wan, DVM, PhD, Food and Drug Administration.
These mouse monoclonal antibodies (IgG1) were raised against the NA of influenza A H7N9 virus A/Anhui/1/2013.
Highlights:
- React with the NA of influenza A H7N9 viruses
- Cross react with the NA of an H11N9 virus (A/tern/Australia/G70C/75)
- Bind to epitopes containing residues 253 (2F6), 334 (7F8), and 370 and 434 (10F4)
- Suitable for ELISA, immunofluorescence assay and NA inhibition assay
- Can be used in NA potency assessment of pre-pandemic H7N9 influenza vaccines
Influenza A H7N9 virus normally infects avian populations but a novel H7N9 reassortant virus emerged in 2013 has caused infections in humans, with ~40% mortality in the confirmed clinical cases. Symptoms include fever, cough, and shortness of breath, which may progress to severe pneumonia. Neuraminidase (NA) is one of the major surface glycoproteins on influenza virus and NA-specific immunity has been shown to provide protection against virus infection. NA is also the major target of FDA-approved antivirals that are used in treating influenza.
From the laboratory of Hongquan Wan, DVM, PhD, Food and Drug Administration.
| Catalog Number | Product | DataSheet | Size | AVAILABILITY | Price | Qty |
|---|
| Product Type: | Antibody |
| Accession ID: | P0DOF9 |
| Isotype: | IgG1 |
| Clonality: | Monoclonal |
| Clone Name: | 2F6, 7F8 or 10F4 |
| Reactivity: | Reacts with the NA of influenza A H7N9 viruses and cross-reacts with NA of an H11N9 virus (A/tern/Australia/G70C/75) |
| Immunogen: | Recombinant NA of influenza A H7N9 A/Anhui/1/2014 |
| Species Immunized: | Mouse |
| Epitope: | 2F6: 250-loop of NA (N9 subtype)7F8: 340-loop of NA (N9 subtype)10F4: 430-loop of NA (N9 subtype) |
| Purification Method: | Protein G |
| Buffer: | PBS, 0.05% (w/v) Sodium Azide |
| Tested Applications: | ELISA, ELLA |
| Storage: | -20C |
| Shipped: | Cold Packs |
- Hongquan W. Li Q. Gao J. Couzens LK. Lianlian J. Gao Y. Sheng ZM. Fong S. Hahn M. Surender K. Jeffery TK. Eichelberger MC. Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection. Journal of Virology. 2018 February. 92(4);e01588017.
If you publish research with this product, please let us know so we can cite your paper.
